<DOC>
	<DOCNO>NCT02200757</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety aldoxorubicin compare topotecan subject metastatic small cell lung cancer .</brief_summary>
	<brief_title>Efficacy Safety Aldoxorubicin Compared Topotecan Subjects With Metastatic Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Age ≥18 year male female . 2 . Histological confirmation SCLC . 3 . Relapsed refractory 1 course systemic therapy regimen incurable either surgery radiation . 4 . Capable provide informed consent comply trial procedure . 5 . ECOG PS 02 . 6 . Life expectancy &gt; 8 week . 7 . Measurable tumor lesion accord RECIST 1.1 criterion . [ 22 ] 8 . Women must able become pregnant ( e.g . postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) 9 . Males female partner ( ) childbearing potential must use 2 form effective contraception ( see Inclusion 8 plus condom vasectomy male ) last menstrual period female partner study treatment 6 month final dose study treatment . 10 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 11 . Accessibility site ensures subject able keep studyrelated appointment . 1 . Prior exposure &gt; 375 mg/m2 doxorubicin liposomal doxorubicin . 2 . Prior treatment topotecan . 3 . Palliative surgery and/or radiation treatment &lt; 21 day prior date randomization . 4 . Exposure investigational agent within 30 day date randomization . 5 . Exposure systemic chemotherapy within 21 day date randomization . 6 . Active ( symptomatic ) central nervous system ( CNS ) metastasis . 7 . History malignancy except cure basal cell carcinoma , cutaneous squamous cell carcinoma , melanoma situ , superficial bladder cancer carcinoma situ cervix unless document free cancer ≥3 year . 8 . Laboratory value : Screening serum creatinine &gt; 1.5×upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3×ULN &gt; 5×ULN liver metastasis present , total bilirubin &gt; 2×ULN , absolute neutrophil count ( ANC ) &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , hemoglobin &lt; 9 g/dL , albumin &lt; 2 gm/dL . 9 . Anion gap &gt; 16 meq/L arterial blood pH &lt; 7.30 . 10 . Clinically evident congestive heart failure ( CHF ) &gt; class II New York Heart Association ( NYHA ) guideline ( Appendix D ) . 11 . Current , serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V ( Appendix F ) . 12 . Baseline QTc &gt; 470 msec measure Fridericia 's formula ( QTcF ) and/or previous history QT prolongation take medication . Concomitant use medication associate high incidence QT prolongation allow . 13 . History sign active coronary artery disease angina pectoris within last 6 month . 14 . Serious myocardial dysfunction define ECHO absolute leave ventricular ejection fraction ( LVEF ) institution 's low limit predict normal . 15 . Known history HIV infection . 16 . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . 17 . Treatment pglycoprotein inhibitor cyclosporine A , elacridar , ketoconazole , ritonavir , saquinavir . 18 . Major surgery within 30 day prior date randomization . 19 . Substance abuse condition might interfere subject 's participation study evaluation study result . 20 . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>